Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Sims

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Elife|July 15, 2016
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
The Journal of Biological Chemistry|February 1, 2021
Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activityJacob I Stuckey, Nico R Cantone, Alexandre Côté, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence TimeAvinash Khanna, Alexandre Côté, Shilpi Arora, et al.
Cell Chemical Biology|May 28, 2026
Covalent PPARγ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARγ/RXRα-activated urothelial carcinomaJacob I Stuckey, Jennifer A Mertz, Jonathan E Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor MicroenvironmentYinshi Huang, Sabikun Nahar, Akifumi Nakagawa, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Elife|July 15, 2016
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
The Journal of Biological Chemistry|February 1, 2021
Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activityJacob I Stuckey, Nico R Cantone, Alexandre Côté, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence TimeAvinash Khanna, Alexandre Côté, Shilpi Arora, et al.
Cell Chemical Biology|May 28, 2026
Covalent PPARγ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARγ/RXRα-activated urothelial carcinomaJacob I Stuckey, Jennifer A Mertz, Jonathan E Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor MicroenvironmentYinshi Huang, Sabikun Nahar, Akifumi Nakagawa, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
Pageof 5